Jul. 4—Jacob McGurn GILEAD — The Oxford County Sheriff’s Office is seeking a 28-year-old Gilead man wanted for firing shots at a man early Thursday morning and being involved in another violent confrontation at a residence in nearby Bethel. Jacob McGurn is wanted on charges of terrorizing, domestic violence criminal threatening with a dangerous weapon, […]
Biotech stocks are back in the news lately. While Gilead Sciences (GILD) has not been a leader this year, it has led bull runs in the past. Thus, let’s focus on a broken wing butterfly trade in GILD stock. ↑ X NOW PLAYING 450% William O’Neil Winner Profited Off Of This Significant Medical Sector Innovation […]
Gilead (GILD) has seen encouraging results from its twice-yearly shot to prevent HIV. Yahoo Finance’s Anjalee Khemlani reports more on the drug and how HIV treatments continue to be the largest contributor to the biotech company’s market capitalization. For more expert insight and the latest market action, click here to watch this full episode of […]
Gilead Sciences (GILD) beat Wall Street’s first-quarter sales forecasts Thursday on the back of its Covid treatment, Veklury. Gilead stock jumped in late trades.
By Deena Beasley (Reuters) – Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion […]
Pharmaceutical sector mainstay Gilead Sciences (NASDAQ: GILD) has had many good days on the stock exchange, but Monday wasn’t one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company’s share price down by more than 10%. And that was on a day when the […]